Research analysts at Barclays Capital (NYSE: BCS) boosted their target price on shares of Vitamin Shoppe (NYSE: VSI) from $44.00 to $52.00 in a report released on Wednesday. The firm currently has an “equal weight” rating on the stock.
Shares of Vitamin Shoppe opened at 54.07 on Wednesday. Vitamin Shoppe has a 52 week low of $34.49 and a 52 week high of $54.91. The company has a market cap of $1.568 billion and a P/E ratio of 35.57.
Vitamin Shoppe last announced its earnings results on Tuesday, May 8th. The company reported $0.61 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.57 by $0.04. Vitamin Shoppe’s revenue was up 14.4% compared to the same quarter last year. On average, analysts predict that Vitamin Shoppe will post $0.43 earnings per share next quarter.
A number of other analysts have also recently weighed in on VSI. Analysts at Goldman Sachs (NYSE: GS) raised their price target on shares of Vitamin Shoppe from $49.00 to $56.00 in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Vitamin Shoppe to $55.00 in a research note to investors on Wednesday. They now have a “market perform” rating on the stock. Finally, analysts at JPMorgan Chase (NYSE: JPM) raised their price target on shares of Vitamin Shoppe from $47.00 to $56.00 in a research note to investors on Wednesday.
Vitamin Shoppe, Inc. is a specialty retailer and direct marketer of vitamins, minerals, herbs, specialty supplements, sports nutrition and other health and wellness products.